Pulmatrix drug candidate receives "Qualified Infectious Disease Product" designation
Pulmatrix announced its drug candidate, PUR1900, has been designated as a "Qualified Infectious Disease Product" by the FDA. Currently, many CF patients experience allergic reactions when their lungs become infected with a fungus called Aspergillus. January 17, 2017